Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
Biomarkers for Brain Disorders: Challenges and Opportunities
Two endogenous retroviral loci appear to contribute to Multiple Sclerosis.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
Treatment satisfaction in multiple sclerosis.
Multiple sclerosis in pregnancy.
Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study.
Treatment of neurological injury with thymosin β4.
Primary infection with the Epstein-Barr virus and risk of multiple sclerosis.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Repurposing drugs for disease modification in multiple sclerosis
Knockdown of Lingo1b protein promotes myelination and oligodendrocyte differentiation in zebrafish.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Pages
« first
‹ previous
…
89
90
91
92
93
94
95
96
97
…
next ›
last »